Creatine’s Potential Beyond Muscle: New Review Explores Link to Depression Relief

The familiar supplement creatine, a cornerstone for athletes seeking to enhance strength and muscle performance, is now under scrutiny for a far more profound potential: alleviating symptoms of depression. A comprehensive systematic review, recently published in the esteemed journal Brain Medicine, has meticulously examined the existing clinical evidence to ascertain whether creatine supplementation might offer a novel therapeutic avenue by bolstering the brain’s crucial energy reserves. While the findings present a landscape of cautious optimism, they underscore the substantial knowledge gaps that still necessitate further rigorous investigation. The review highlights a dichotomy in results, with some trials reporting significant improvements in depressive symptoms, while others found no discernible benefit, leaving the scientific community with more questions than definitive answers.

Unraveling the Evidence: A Deep Dive into Clinical Trials

Rather than initiating new experimental research, a team of dedicated researchers, spearheaded by Bassam Jeryous Fares from the University of Ottawa, undertook the crucial task of synthesizing and analyzing all available published studies. This systematic review meticulously sifted through the existing literature, ultimately identifying six distinct reports that encompassed five randomized controlled trials. In these trials, participants were assigned to receive either creatine or a placebo, with neither the participants nor the researchers directly involved in administering the treatment aware of the allocation – a crucial step in minimizing bias.

The geographical distribution of these foundational studies is noteworthy, spanning research institutions in South Korea, the United States, Brazil, Israel, and India. Collectively, these trials began with 238 participants. Of these, 126 individuals were allocated to receive creatine, while 112 were given a placebo. The average age of participants hovered around 36 years, with a notable majority being women. In fact, two of the five included studies specifically enrolled exclusively female participants, a demographic characteristic that warrants careful consideration when interpreting the findings.

The clinical focus of these trials varied slightly. Four of the five studies zeroed in on individuals diagnosed with major depressive disorder, a prevalent and often debilitating mental health condition. The fifth study, however, broadened its scope to include participants with bipolar disorder who were experiencing a depressive episode. The inherent heterogeneity in the design and methodological approaches employed across these distinct studies prevented the researchers from performing a single, overarching statistical analysis. Consequently, the review opted for a more granular approach, evaluating the outcomes of each study individually to glean nuanced insights.

A Dichotomous Landscape: Mixed Results in Depression Studies

The systematic review unveiled a decidedly divided picture regarding creatine’s efficacy in managing depression. Two of the five rigorously reviewed trials, both of which specifically involved women diagnosed with major depressive disorder, reported that creatine supplementation yielded tangible additional benefits.

In one of these pivotal studies, participants who received five grams of creatine daily in conjunction with their prescribed antidepressant, escitalopram, demonstrated significantly greater reductions in depressive symptoms after an eight-week treatment period compared to those who received escitalopram alongside a placebo. The magnitude of this improvement was substantial by conventional statistical standards, registering a Cohen’s d of 1.13 on the widely recognized Hamilton Depression Rating Scale. Furthermore, a higher proportion of participants in the creatine group achieved clinical remission from their depressive symptoms.

In a separate, equally encouraging study, creatine was paired with cognitive behavioral therapy (CBT), a widely adopted psychotherapeutic approach. In this trial, participants who received creatine alongside CBT exhibited a more pronounced reduction in depression symptoms, as measured by a standardized assessment tool, when contrasted with the control group that received therapy with a placebo. These findings collectively suggest a potential synergistic effect when creatine is combined with established depression treatments.

However, the remaining three trials presented a starkly different narrative, reporting no statistically significant or clinically meaningful benefit from creatine supplementation. One study, in particular, investigated the impact of both five and ten grams of creatine daily on individuals whose depression had proven resistant to conventional medication. The results indicated that neither dosage led to any improvement in their depressive symptoms. Another trial, focusing on adolescent girls, found no discernible advantage of creatine over a placebo, even when various dosages were explored. A third study, which included participants diagnosed with bipolar disorder experiencing a depressive episode, also failed to demonstrate any positive impact of creatine on their mood symptoms.

Beyond the efficacy data, the review also brought to light an important safety consideration. In two participants diagnosed with bipolar disorder who were administered creatine, adverse events manifested as hypomania or mania. This observation raises a critical flag, suggesting that creatine’s impact on mood may be modulated by an individual’s underlying psychiatric condition, necessitating careful monitoring in such populations.

The Neurobiological Underpinnings: Why Creatine Might Influence Brain Health

The scientific rationale for investigating creatine’s potential role in depression is rooted in the brain’s remarkably high energy demands. The brain, despite comprising only about 2% of the body’s weight, accounts for approximately 20% of the body’s total energy consumption. This immense energetic requirement underscores the critical importance of efficient cellular energy production for optimal brain function.

Creatine is most renowned for its role in facilitating the rapid regeneration of adenosine triphosphate (ATP), the universal energy currency of cells, particularly within muscle tissue. However, the brain also relies heavily on this same energy system to power its complex array of functions, including neurotransmission, synaptic plasticity, and cognitive processes. Previous research has identified alterations in brain creatine metabolism in individuals with various mood disorders, prompting scientific inquiry into whether disruptions in cellular energy production might, in fact, contribute to the pathophysiology of depression.

Furthermore, emerging evidence suggests that creatine may also exert influence over key neurotransmitters implicated in mood regulation, namely dopamine and serotonin. These neurotransmitters are the primary targets of many widely prescribed antidepressant medications, and their dysregulation is strongly associated with the development and persistence of depressive symptoms. By potentially modulating the availability or activity of these crucial neurochemical messengers, creatine could, in theory, contribute to mood stabilization.

Despite these plausible biological mechanisms, the authors of the review strongly emphasize that these connections remain largely theoretical at this juncture. The existing studies primarily demonstrate correlations rather than establishing definitive causal links. While altered creatine metabolism has been observed in individuals with depression, this does not unequivocally prove that such alterations directly cause the disorder. Depression is a complex, multifactorial condition influenced by a constellation of genetic, environmental, and biological factors.

Bassam Jeryous Fares, the lead author of the review and a student at the University of Ottawa’s Faculty of Medicine, articulated this sentiment with precision: "The signal is interesting, but it is not a verdict," he stated. "Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration."

Nicholas Fabiano, the corresponding author of the review and a psychiatry resident at the University of Ottawa, echoed this call for caution. "Creatine appears to be a safe intervention. The adverse events we found were limited to mild gastrointestinal discomfort," he noted. "We cannot yet reliably say that creatine helps with depressive symptoms or if the findings are generalizable to everyone."

The Imperative for Larger, More Robust Studies

The researchers involved in this comprehensive review unequivocally stress that the current body of evidence is too limited to warrant the routine or widespread use of creatine as a treatment for depression. The clinical trials that have been conducted thus far, while valuable, suffer from several limitations that hinder their broader applicability.

Primarily, the trials were relatively small in sample size, which can limit the statistical power to detect subtle but meaningful effects. Moreover, the participant demographics were not representative of the general population experiencing depression, with a disproportionate number of women included compared to men. This gender imbalance is particularly significant given the potential for differential responses to interventions.

The quality of the studies also presented a challenge. While two of the five trials were assessed as having a low risk of bias, the remaining three raised some concerns. These concerns primarily pertained to aspects such as the methods used for participant assignment to treatment groups and the handling of missing data, both of which can introduce potential biases and affect the reliability of the findings. Consequently, the conclusions drawn from these studies cannot yet be broadly generalized to diverse patient populations.

In light of these limitations, the systematic review issues a clear call for larger, longer-term clinical trials. Such studies are essential to provide more definitive answers about creatine’s efficacy and safety in treating depression. Researchers recommend extending the duration of these trials beyond the typical eight-week period, as depressive symptoms can fluctuate and treatment effects may take longer to become apparent.

Furthermore, the review suggests investigating creatine’s effects in conjunction with other established interventions, such as exercise. Physical activity is a well-documented adjunct therapy for depression, and exploring potential synergistic benefits with creatine could uncover new treatment strategies. The research community also advocates for exploring whether different dosages of creatine might yield varying outcomes, while simultaneously acknowledging that higher doses do not necessarily equate to greater benefits and may increase the risk of adverse effects.

Intriguingly, findings from animal studies may offer additional clues to understanding potential gender-specific responses. Experiments conducted on rodents have demonstrated that creatine can influence depression-like behaviors differently in male and female animals. This observation could potentially shed light on why the human studies that predominantly included women yielded the most pronounced positive results.

Conclusion: An Intriguing Possibility on the Horizon

For the present moment, creatine remains an intriguing possibility rather than a scientifically validated treatment for depression. The supplement, long associated with the pursuit of physical prowess and muscular development, is now capturing the attention of scientists who are diligently searching for novel and effective strategies to combat the pervasive challenge of mental health disorders. The ongoing exploration into creatine’s neurobiological effects signifies a dynamic and evolving landscape in the quest for improved mental well-being.

The peer-reviewed research article, titled "Creatine as a treatment for depression," was published in Brain Medicine and has been made available through Open Access, commencing June 30, 2026, allowing for broader dissemination and further scientific discourse. The continued investigation into this versatile compound promises to be a significant area of research in the years to come.